Clinical trial
Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis
NCT00269867 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00269867 |
|---|---|
| Title | Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis |
| Official title | A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Placebo, Infliximab 3 mg/kg, Infliximab 10 mg/kg |
| Enrollment | 428 |
| Start date | Mar 1, 1997 |
| Primary completion | Mar 1, 2000 |
| Completion | Mar 1, 2000 |
| First posted | Dec 26, 2005 |
| Last update posted | Nov 4, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: